339 related articles for article (PubMed ID: 33232506)
21. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
[TBL] [Abstract][Full Text] [Related]
22. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Del Re M; Cinieri S; Michelucci A; Salvadori S; Loupakis F; Schirripa M; Cremolini C; Crucitta S; Barbara C; Di Leo A; Latiano TP; Pietrantonio F; Di Donato S; Simi P; Passardi A; De Braud F; Altavilla G; Zamagni C; Bordonaro R; Butera A; Maiello E; Pinto C; Falcone A; Mazzotti V; Morganti R; Danesi R
Pharmacogenomics J; 2019 Dec; 19(6):556-563. PubMed ID: 30723313
[TBL] [Abstract][Full Text] [Related]
23. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
24. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
[TBL] [Abstract][Full Text] [Related]
25. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
26. Diversity of oncopharmacogenetic profile within Spanish population.
Ferrer Bolufer I; Galiana Vallés X; Izquierdo Álvarez S; Serrano Mira A; Guzmán Luján C; Safont Aguilera MJ; González Tarancón R; Bolaños Naranjo M; Carrasco Salas P; Santamaría González M; Rodríguez-López R
Pharmacogenet Genomics; 2024 Jul; 34(5):166-169. PubMed ID: 38488402
[TBL] [Abstract][Full Text] [Related]
27. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
Medwid S; Wigle TJ; Kim RB
Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
[TBL] [Abstract][Full Text] [Related]
28. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
29. A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature.
Conti V; De Bellis E; Manzo V; Sabbatino F; Iannello F; Dal Piaz F; Izzo V; Charlier B; Stefanelli B; Torsiello M; Iannaccone T; Coglianese A; Colucci F; Pepe S; Filippelli A
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32899374
[TBL] [Abstract][Full Text] [Related]
30. Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population.
Botton MR; Hentschke-Lopes M; Matte U
Ann Hum Genet; 2022 Mar; 86(2):102-107. PubMed ID: 34897655
[TBL] [Abstract][Full Text] [Related]
31. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
32. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
[TBL] [Abstract][Full Text] [Related]
33. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis.
Sharma BB; Rai K; Blunt H; Zhao W; Tosteson TD; Brooks GA
Oncologist; 2021 Dec; 26(12):1008-1016. PubMed ID: 34506675
[TBL] [Abstract][Full Text] [Related]
34. Survival of Patients With Cancer With
Knikman JE; Wilting TA; Lopez-Yurda M; Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Nieboer P; Droogendijk HJ; Creemers GJ; Mandigers CMPW; Imholz ALT; Mathijssen RHJ; Portielje JEA; Valkenburg-van Iersel L; Vulink A; van der Poel MHW; Baars A; Swen JJ; Gelderblom H; Schellens JHM; Beijnen JH; Guchelaar HJ; Cats A
J Clin Oncol; 2023 Dec; 41(35):5411-5421. PubMed ID: 37639651
[TBL] [Abstract][Full Text] [Related]
35. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
37. Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
Wong BYL; Li Z; Raphael MJ; De Angelis C; Hwang DM; Fu L
J Appl Lab Med; 2024 Mar; 9(2):295-304. PubMed ID: 38084968
[TBL] [Abstract][Full Text] [Related]
38. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
[TBL] [Abstract][Full Text] [Related]
39. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
